Snipr Biome is a synthetic biology company using CRISPR to make products for the microbiome that is headquartered in Copenhagen, Denmark and was founded in 207 by Christian Grondahl, Morten O.A. Sommer, and Jasper Clube. Snipr Biome uses CRISPR systems the company calls CRISPR-Guided Vectors to target and kill specific bacterial species living within the human microbiome while leaving all other strands of bacteria intact .
Snipr Biome has been granted a total of 5 patents (as of September 2019), they are: US9701964, US10195273, US10300138, US10300139, and US10363308.
On March 11, 2019 Snipr Biome completed their series A funding round with $50 million in funding from Lundbeckfonden Emerge (lead investor), LSP (lead investor), North-East Family Office, and Wellington Partners. The company plans on using their series A funding to further develop their CRISPR technology platform and fund the companies first clinical trials. The co-founder and CEO of Snipr Biome, Dr. Christian Grondahl, made the following statement to reporters regarding his companies series A funding:
We have the potential to develop valuable therapeutics within multiple important disease areas. We will focus initially on precision medicines for difficult-to-treat infections and precision microbiome modulation in auto-immunity and cancer. We are utilizing the bacteria’s CRISPR/Cas immune system to selectively kill target bacteria based on specific DNA fingerprints. We are thrilled to have obtained this massive and transformational funding and backing from absolute leading European VCs and investors in Lundbeckfonden Emerge, Life Science Partners, North-East Family Office, and Wellington Partners.